Franklin Street Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Franklin Street Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-30,000	Closed	-$510K	–	155
2020 Q4	$510K	Sell	30,000 -20,000	-40%	-$251K	0.05%	103
2020 Q3	$235K	Hold	50,000	–	–	0.03%	127
2020 Q2	$305K	Hold	50,000	–	–	0.04%	116
2020 Q1	$114K	Buy	50,000 +20,000	+67%	+$84.9K	0.02%	132
2019 Q4	$138K	Hold	30,000	–	–	0.02%	149
2019 Q3	$116K	Hold	30,000	–	–	0.01%	152
2019 Q2	$181K	Hold	30,000	–	–	0.02%	152
2019 Q1	$402K	Buy	30,000 +20,000	+200%	+$228K	0.06%	112
2018 Q4	$93K	Hold	10,000	–	–	0.01%	141
2018 Q3	$139K	Hold	10,000	–	–	0.02%	153
2018 Q2	$158K	Hold	10,000	–	–	0.02%	152
2018 Q1	$172K	Sell	10,000 -15,000	-60%	-$293K	0.03%	154
2017 Q4	$548K	Buy	+25,000	New	+$804K	0.08%	102
2017 Q1	–	Sell	-5,000	Closed	-$251K	–	180
2016 Q4	$251K	Hold	5,000	–	–	0.04%	152
2016 Q3	$262K	Buy	+5,000	New	+$239K	0.05%	159

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Franklin Street Advisors's FPRX Position: Q1 2021 in Review

Franklin Street Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 30,000 shares — an estimated $510K sold.

Franklin Street Advisors first reported a position in FPRX in Q3 2016 and held it in 15 quarters. The position peaked at $548K in Q4 2017. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

Franklin Street Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Franklin Street Advisors sold 30,000 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $510K.
Franklin Street Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 15 quarters.
Franklin Street Advisors's Five Prime Therapeutics, Inc. position peaked at $548K in Q4 2017.
147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Franklin Street Advisors's 13F filing for Q1 2021, filed 4 May 2021.